Omnipod® 5 price made simple.

Try it with a free demo Pod

Flexible, Pay‑As‑You‑Pod insulin pump therapy

Omnipod® 5 automatically adjusts insulin every 5 minutes, designed to simplify life with type 1 diabetes. Now available with NDSS partial subsidy.

 

Simple pricing. No surprises.

Without private insurance

  • Subscription payment to Omnipod Australia (per box): $185 
  • NDSS co-payment^ paid at the pharmacy (per box):  $35.30 

Key benefits:

  • No lock in subscription, no commitment.
  • No upfront pump cost
  • Pay‑As‑You‑Pod

 

With private insurance

NDSS co-payment^ paid at the pharmacy (per box): $35.30 general 

A patient receives Pods from a pharmacist at the pharmacy. A patient receives Pods from a pharmacist at the pharmacy.

Have questions? We’re here to help

Talk to an Omnipod specialist to discuss subscription options, NDSS requirements, and next steps.

Get personalised support


Real results, from real people

Proven clinical outcomes, and meaningful impact on everyday life.

Proven to improve Time in Range1,2

Over 80% 

Time in Range with optimised settings3

Designed to make life easier.4

96% 

say it’s easy to use

Less overthinking. Less worrying.5

92%

say it gives them peace of mind

3 - Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 6.1-6.4 mmol/L (110- 115 mg/dL). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.

Why people choose Omnipod

Tubeless and waterproof†

woman sitting by the pool woman sitting by the pool

No tubes, no tangles. Wear your Pod in the shower, swimming pool or sea†! 

Automated insulin delivery, day and night

man sleeping and has pod placed on upper arm man sleeping and has pod placed on upper arm

Adjusts insulin delivery every 5 minutes, so you don't have too.

No more multiple daily injections

young girl with hands raised young girl with hands raised

It can replace over 1,634 injections a year.6

PEK | Simplify life Omnipod® PEK | Simplify life Omnipod®

Not sure if it’s right for you?

If you’d like to experience how Omnipod feels on your body, you can request a free demo Pod*.

A demo Pod* lets you:

  • Test comfort and adhesion
  • See how it fits into your routine
  • Understand the size and wearability

Make an informed decision before subscribing

Get your free demo pod

Don’t just take our word for it

From the first few weeks, I realised how much mental space it freed up.

Sevanah
Podder® since 2024

Omnipod 5 has allowed us to give Priya the freedom that all kids deserve, whilst not compromising her safety or worrying about disconnecting her from her insulin delivery

Kimmie – Mother of Priya
Podder® since 2023

The three words I use to describe Omnipod are simple easy freedom.

Scott
Living with T1 for 35 years
Podder since 2024

Try it for yourself

Nothing beats firsthand experience. The free Pod Experience Kit* (PEK) contains a needle-free nonfunctioning demo Pod for you to wear. It also includes a quick-start guide providing you with more information about the Omnipod® System.

Indicates required field
Preferred Contact Time
1,2 - Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs 6.78% or 55 mmol/mol vs. 51 mmol/mol, P<0.0001; 7.67% vs 6.99% or 60mmol/mol vs 53 mmol/mol), P<0.0001). Mean time in hypoglycaemic range in adults/adolescents (<3.9 mmol/L or <70mg/dL as measured by CGM) as measured by CGM: ST = 1.89%, 3-mo Omnipod 5 = 1.32%, P<0.0001. Mean time in hypoglycaemic range in children (<3.9 mmol/L or <70mg/dL as measured by CGM): ST = 2.21%, 3-mo Omnipod 5 = 1.78%, P<0.0456.
Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5system. Mean HbA1c as measured in very young children, ST vs. Omnipod 5 use:7.4% vs 6.9% or 57 mmol/ml vs. 53 mmol/mol; (P<0.0001). Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time in hypoglycaemic range (<3.9mmol/L or <70 mg/dL as measured by CGM) ST = 3.43% vs Omnipod 5: 2.46%, P<0.0001. Study funded by Insulet

3 - Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 6.1-6.4 mmol/L (110-115 mg/dL). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.

4 - 2025 Customer Survey of U.S. adults with Type 1 diabetes, n=70, 92% agreed Omnipod 5 is easy to use

5 - 2025 Customer Survey of U.S. adults with Type 1 diabetes (n=1230), 92% agreed Omnipod 5 gives them peace of mind. Survey funded by Insulet.

6 - Chiang et al. Diabetes Care. 2014:37:2034-2054. 1,643 injections in a year based on people with type 1 diabetes on multiple daily injections taking ≥ 3 bolus and 1-
2 basal injections/day (~4.5/day).